Use este identificador para citar ou linkar para este item: http://repositorio.ufla.br/jspui/handle/1/41577
Registro completo de metadados
Campo DCValorIdioma
dc.creatorGarcía, Leidy Y.-
dc.creatorCerda, Arcadio A.-
dc.date.accessioned2020-06-26T11:56:33Z-
dc.date.available2020-06-26T11:56:33Z-
dc.date.issued2020-
dc.identifier.citationGARCÍA, L. Y.; CERDA, A. A. Contingent assessment of the COVID-19 vaccine. Vaccine, [S.l.], 2020. No prelo.pt_BR
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0264410X20308549pt_BR
dc.identifier.urihttp://repositorio.ufla.br/jspui/handle/1/41577-
dc.description.abstractThe COVID-19 pandemic has not only had a negative impact on people’s health and life behavior, but also on economies around the world. At the same time, laboratories and institutions are working hard to obtain a COVID-19 vaccine, which we hope will be available soon. However, there has been no assessment of whether an individual and society value ​​a vaccine monetarily, and what factors determine this value. Therefore, the objective of this research was to estimate the individual’s willingness to pay (WTP) for a hypothetical COVID-19 vaccine and, at the same time, find the main factors that determine this valuation. For this, we used the contingent valuation approach, in its single and double-bounded dichotomous choice format, which was based on a hypothetical market for a vaccine. The sample used was obtained through an online survey of n = 566 individuals from Chile. The main results showed that the WTP depends on the preexistence of chronic disease (), knowledge of COVID-19 (), being sick with COVID-19 (), perception of government performance (), employment status (), income (), health care (), adaptation to quarantine with children at home ( and whether the person has recovered from COVID-19 (. According to our discrete choice model in double-bounded dichotomous format, it was concluded that the individuals’ WTP is US$184.72 (CI: 165.52-203.92; p < 0.01). This implies a social valuation of approximately US$2,232 million, corresponding to 1.09% of the GNP per capita.pt_BR
dc.languageen_USpt_BR
dc.publisherElsevierpt_BR
dc.rightsrestrictAccesspt_BR
dc.sourceVaccinept_BR
dc.subjectCOVID-19pt_BR
dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)pt_BR
dc.subjectVaccinept_BR
dc.subjectHealth economicspt_BR
dc.subjectContingent valuationpt_BR
dc.titleContingent assessment of the COVID-19 vaccinept_BR
dc.typeArtigopt_BR
Aparece nas coleções:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Arquivos associados a este item:
Não existem arquivos associados a este item.


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.